Trial Profile

A Phase 2 study of THB335 inpatients with chronic spontaneous urticaria

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THB 335 (Primary)
Indications Chronic urticaria
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Feb 2025 According to a Third Harmonic Bio media release, The Company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study in CSU by mid-year 2025.
08 Aug 2024 According to a Third Harmonic Bio media release, results expected in the first quarter of 2025.
30 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com